Fig. 1From: Metabolic syndrome biomarkers relate to rate of cognitive decline in MCI and dementia stages of Alzheimer’s diseaseIllustrative plots representing multivariable linear mixed effect model slope and 95% confidence interval results for analytes (TG/HDL, plasma APOA1) versus longitudinal CDR-SB score at the first-quartile and third quartiles in the MCI group (n = 106) or dementia group (n = 50)Back to article page